The United Nations Office at Geneva
Multimedia Newsroom
COVID-19: UN health agency issues conditional advice against using remdesivir
Patients with COVID-19 should not be given the antiviral drug remdesivir “regardless of disease severity”, the UN World Health Organization (WHO) said on Friday.
Nonetheless, describing its recommendation as “conditional”, as opposed to “strong”, WHO stressed that data from a global trial on the efficacy of remdesivir was inconclusive, and that further trials should continue into its use for more vulnerable patients.
“We recommend a conditional recommendation – I want to highlight that - against the use of remdesivir in hospitalised patients with COVID-19 regardless of disease severity,” said Dr Janet Diaz, Head of Clinical Care at WHO, during a virtual press conference in Geneva.
According to data from the WHO-led Solidarity trial which was then examined by a panel of international experts behind the recommendation, “possibly remdesivir can lead to 29 fewer deaths per 1,000 patients or up to 11 more deaths per 1000 patients”, Dr Diaz said. “So you can see that …the confidence interval are relatively large…there was no evidence that there was any important effect on mortality, on the need for mechanical ventilation or the time to clinical improvement.”
But this did “not prove” that the antiviral “had no benefit at all”, Dr Diaz insisted. “There could still be potential small benefit, maybe in a health sub-group which is why the panel also recommended continued trials, continued enrolment into clinical trials.”
The WHO official explained that this might be “severe patients versus critical patients” or whether the antiviral is used “early versus late”.
Dr Bram Rochwerg, who was among the experts advising WHO, noted that there would likely be regional “variations” in the use of remdesivir.
While a minority of people will still choose to use it, the majority would not, based on the available data, he said.
“There may be groups (who might benefit) and the data was a bit more of a close call, so that’s why we felt strongly that trials need to continue using remdesivir and studying remdesivir and looking to see if there are specific groups that might, that might benefit,” he said. “We were very explicit that we do believe that these studies need to continue (and) Solidarity is continuing.”
Although the remdesivir development mirrors similar attempts to use other antivirals against the new coronavirus, Dr Diaz said there was no reason to lose hope in the fight against COVID-19.
“I do think there is a tremendous global effort to investigate treatments. You know, I think a lot of interest was done upfront with the repurposed of drugs, repurposed antivirals, you know we saw that with other repurposed drugs such as hydroxychloroquine, lopinavir, and there was a big push to try to test these and they’ve been tested and unfortunately, we just haven’t, you know, the results haven’t been as promising as we had hoped. But I don’t want to forget that we do have one lifesaving drug and even though it’s a repurposed old, old drug dexamethasone, a corticosteroid, we do know that that does reduce mortality, save lives of patient with severe and critical so there is something.”
Latest data from WHO indicates that eight in 10 people infected with COVID report mild symptoms, Dr Diaz said.
“Since the beginning (of the pandemic)…about 80 per cent of people have, you know, mild disease, a proportion maybe moderate disease and then only a small proportion, a smaller proportion, 20 per cent go on to develop severe or critical disease, and critical disease is a small, small portion, it’s five per cent or less, and that is…and that seems to be kind of consistent I think through the literature so most patients do have, if they have mild disease, self-limiting disease, they get better on their own, their immune system kicks in and they get better.”
Nonetheless, there are reports of more “persistent longer-term symptoms”, Dr Diaz noted. “So even though they don’t get severe disease there can be some persistent symptoms that lasts longer than one would have hoped for.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “We recommend a conditional recommendation - so I want to highlight that, it’s a conditional recommendation - against the use of remdesivir in hospitalized patients - with COVID-19, regardless of disease severity.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “Possibly remdesivir can lead to 29 fewer deaths par 1,000 patients or up to 11 more deaths per 1,000 patients so you can see that this is, the confidence interval is a little bit large.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “It was not clear that, there was no evidence, that there was any important effect on mortality, on the need for mechanic ventilation or the time to clinical improvement.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “This did not prove that remdesivir does not have a benefit at all and that’s why it is a conditional recommendation, there can still be potential small benefit, maybe in a health sub-group, which is why the panel also recommended continued trials, continued enrolment into clinical trials.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “You know, is there a sub-group that may benefit more – such as severe patients versus critical patients. Is there a timing in disease that may benefit more - such as early versus late - and those are all considerations that are in the guidelines.”
- SOUNDBITE (English) — Dr Bram Rochwerg, practising ITU clinician and expert adviser for WHO-led Solidarity Trial: “There may be groups and the data was a bit more of a close call, so that’s why we felt strongly that trials need to continue using remdesivir and studying remdesivir and looking to see if there are specific groups that might, that might benefit. And as she said, we were very explicit that we do believe that these studies need to continue, Solidarity is continuing, so.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “I do think there is a tremendous global effort to investigate treatments. You know, I think a lot of interest was done upfront with the repurposed of drugs, repurposed antivirals, you know we saw that with other repurposed drugs such as hydroxychloroquine, lopinavir, and there was a big push to try to test these and they’ve been tested and unfortunately, we just haven’t, you know, the results haven’t been as promising as we had hoped. But I don’t want to, I don’t want to forget that we do have one lifesaving drug and even though it’s a repurposed old, old drug dexamethasone, a corticosteroid, we do know that that does reduce mortality, save lives of patient with severe and critical so there is something.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “Since the beginning, is that about 80 per cent of people have, you know, mild disease, a proportion maybe moderate disease and then only a small proportion, a smaller proportion, 20 per cent go on to develop severe or critical disease, and critical disease is a small, small portion, it’s five per cent or less, and that is…and that seems to be kind of consistent I think through the literature so most patients do have, if they have mild disease, self-limiting disease, they get better on their own, their immune system kicks in and they get better.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “We do know that even patients with mild disease may have persistent longer-term symptoms. And that has been now described; so even though they don’t get severe disease there can be some persistent symptoms that lasts longer than one would have hoped for.”
Similar Stories
1
1
1
Edited News | OHCHR , UNOG
The appointment on Thursday of Karla Quintana as head of the Independent Institution on Missing Persons in the Syrian Arab Republic is a key development after nearly a year and a half of work by the UN Human Rights Office supporting the institution’s launch.
1
1
1
Edited News | IOM , UNICEF , UNRWA , WHO
The head of the UN migration agency stressed on Friday that Syria is in no position to take back millions of Syrians following the fall of the Assad regime, while there is an urgent need to “re-evaluate” sanctions impacting the war-ravaged country.
1
1
1
Edited News | IIIM , UNHCR
Syria: ‘Key priority’ is to preserve evidence of crimes – UN investigators
In Syria, new access to evidence of horrific human rights violations means that accountability may be closer than ever – if only proof can be preserved, a top UN investigator said on Tuesday.
1
1
1
Edited News | OSE , ICRC , UNHCR
Syria: UN and partners urge action to preserve evidence of prison atrocities, stabilize country
Since the fall of Bashar al-Assad's regime in Syria five days ago, hundreds of people have rushed to Saydnaya prison, desperate to find loved ones. Disturbing images from the prison and other detention centers have since surfaced, exposing the “unimaginable barbarity Syrians have endured for years,” said Jenifer Fenton, spokesperson for the UN special envoy for Syria, on Friday.
1
1
2
Edited News | UNRWA
Gaza: “Sickening normalisation” of suffering, amid attacks on people and aid convoys
Ongoing military operations by the Israeli Defence Forces (IDF) in Gaza continue to devastate Palestinian children and families, with mounting casualties and a critical lack of humanitarian aid for the desperate population.
“Local media reporting here that last night, 30 people were killed in this area in strikes” said a senior emergency officer with the United Nations agency for Palestinian refugees (UNRWA), Louise Wateridge, speaking to reporters in Geneva from central Gaza.
2
1
2
Press Conferences , Edited News | OHCHR
Rights experts call for end to impunity for Israel’s violations of international law
Four independent human rights experts have jointly called for the international community to sanction Israel’s conduct of hostilities in the Occupied Palestinian Territory as well as in the wider Middle East region - including in Syria, Lebanon and Iran. They also called for the restoration of trust in the international justice system through the abandonment of “extreme interpretations” and “double standards” in the application of the universal norms regulating the conduct of war.
1
1
1
Edited News | OCHA , UNHCR
Syria: needs continue to grow amid highly uncertain situation, say aid teams
The historic power shift in Syria and the still volatile situation two days after the fall of Bashar al-Assad’s regime have increased humanitarian needs in a country where nearly 17 million people, including millions of internally displaced, already depended on humanitarian aid before the recent events, UN aid teams said on Tuesday.
2
1
3
Edited News , Press Conferences | OSES
Barely 48 hours since opposition forces including Hayat Tahrir al-Sham (HTS) swept into Damascus and forced out President Bashar al-Assad, the top UN negotiator tasked with helping Syrians’ create a peaceful and democratic future insisted that nothing could be taken for granted.
1
1
1
Edited News | OHCHR , UNOG
UN High Commissioner for Human Rights Chief Volker Türk on Monday called on States to do all in their power to end senseless conflicts and suffering.
1
1
1
Edited News | WHO
No evacuation order given before Kamal Adwan Hospital strike, says WHO
One of the last partially functional health centres in northern Gaza was reportedly hit again overnight into Friday by several strikes, leaving four health workers among the casualties and the dead, according to the UN World Health Organization (WHO).
2
1
2
Edited News , Press Conferences | OCHA
More than 280,000 people have been uprooted in northwest Syria in a matter of days following the sudden and massive offensive into Government-controlled areas led by Hayat Tahrir al-Sham (HTS), which is sanctioned by the Security Council as a terrorist group.
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Chief Volker Türk has called on the Georgian authorities to respect and protect the rights to freedoms of expression and peaceful assembly following several nights of protests that were marred by violence, and dispersed using disproportionate, and in some cases unnecessary, force by the police in the capital, Tbilisi.